$1.72
4.88% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US2312692005
Symbol
CRIS

Curis, Inc. Stock price

$1.72
+0.12 7.50% 1M
-1.21 41.30% 6M
-1.34 43.79% YTD
-3.54 67.30% 1Y
-16.39 90.50% 3Y
-18.28 91.40% 5Y
-254.28 99.33% 10Y
-447.28 99.62% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+0.08 4.88%
ISIN
US2312692005
Symbol
CRIS
Industry

Key metrics

Basic
Market capitalization
$21.5m
Enterprise Value
$11.4m
Net debt
positive
Cash
$10.1m
Shares outstanding
10.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.9 | 1.9
EV/Sales
1.0 | 1.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-14.5%
Return on Equity
723.4%
ROCE
-385.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$11.4m | $11.1m
EBITDA
$-37.8m | $-42.0m
EBIT
$-38.0m | $-35.7m
Net Income
$-38.9m | $-30.9m
Free Cash Flow
$-30.5m
Growth (TTM | estimate)
Revenue
12.3% | 1.4%
EBITDA
23.3% | 5.2%
EBIT
23.4% | 20.0%
Net Income
18.2% | 28.9%
Free Cash Flow
28.7%
Margin (TTM | estimate)
Gross
99.4%
EBITDA
-331.4% | -379.9%
EBIT
-332.9%
Net
-341.3% | -279.1%
Free Cash Flow
-267.1%
More
EPS
$-3.1
FCF per Share
$-2.8
Short interest
1.4%
Employees
34
Rev per Employee
$320.0k
Show more

Is Curis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Curis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Curis, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Curis, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Curis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
11 11
12% 12%
100%
- Direct Costs 0.07 0.07
59% 59%
1%
11 11
14% 14%
99%
- Selling and Administrative Expenses 15 15
24% 24%
128%
- Research and Development Expense 35 35
14% 14%
304%
-38 -38
23% 23%
-331%
- Depreciation and Amortization 0.18 0.18
28% 28%
2%
EBIT (Operating Income) EBIT -38 -38
23% 23%
-333%
Net Profit -39 -39
18% 18%
-341%

In millions USD.

Don't miss a Thing! We will send you all news about Curis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Curis, Inc. Stock News

Neutral
PRNewsWire
one day ago
LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held Sep...
Positive
The Motley Fool
29 days ago
Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.
Neutral
Seeking Alpha
30 days ago
Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Accounting Officer James E.
More Curis, Inc. News

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Head office United States
CEO James Dentzer
Employees 34
Founded 2000
Website www.curis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today